Trials / Completed
CompletedNCT00426036
Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine
An Open-Label Study in Healthy Subjects and in Patients With Stable Impaired Renal Function to Assess the Effect of Severe Renal Impairment on Licarbazepine Pharmacokinetics and Metabolism After the Single Administration of a 500 mg Licarbazepine Immediate Release (IR) Tablet
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the influence of severe renal impairment on the pharmacokinetics of licarbazepine and its glucuronide conjugate after single oral administration in healthy subjects and in subjects with stable impaired renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Licarbazepine |
Timeline
- Start date
- 2006-06-01
- First posted
- 2007-01-24
- Last updated
- 2007-06-22
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT00426036. Inclusion in this directory is not an endorsement.